PhoenixBio established its proprietary chimeric mouse model, the PXB-mouse®, with a highly humanized liver through years of research and development. With the addition of fresh, isolated human hepatocytes, PXB-cells®, the applications of our products and study services are as wide-ranging as our clients’ research goals. The PXB-mouse animal background (cDNA-uPA/SCID) makes for a robust, consistent model that maintains up to 95% stable human hepatocyte engraftment. The reconstituted humanized liver features structural and biological characteristics commonly observed in normal human livers. The model has proven to be a world-wide gold standard for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) research, but usage is expanding in the fields of: . Drug Metabolism and Pharmacokinetics, · Human Specific Hepatotoxicity, · Oligonucleotide and Gene-based Therapeutics, · HBV & HBV/HDV, · NASH/NAFLD, · Other human liver-related research fields. PXB-cells® are approximately 95% pure human hepatocytes freshly isolated from the PXB-mouse®. They feature long-term stability of up to 40 days, and allow for consistent supply from the same donor. One unique feature of PXB-cells® and PXB-mice is the ability to directly compare in vitro and in vitro data from the same human donor. With over 300 scientific publications to its credit, the PXB-mouse is the world’s most widely used chimeric mouse model with a humanized liver. A high replacement index, lifespan of up to 2 years, and no secondary drug to maintain mouse liver injury means that your data can translate better to humans than ever before. Please visit our website at https://www.phoenixbio.com/ to learn more about our model and inquire about our offered products and services.
| Website | https://www.phoenixbio.com/ |
| Revenue | $9.8 million |
| Employees | 23 (9 on RocketReach) |
| Founded | 2002 |
| Address | 3-4-1 Kagamiyama, Higashi Hiroshima, Hiroshima 739 0046, JP |
| Phone | +81 82-431-0016 |
| Fax | (212) 379-6422 |
| Technologies |
JavaScript
,
HTML
,
PHP
+10 more
(view full list)
|
| Industry | Biotechnology Research, Manufacturing General, Manufacturing |
| Web Rank | 3 Million |
| Keywords | フェニックスバイオ, Phoenix Bio, フェニックス バイオ 吉里 勝利, 動物実験 受託, フェニックスB |
| Competitors | Thermo Fisher Scientific, Charles River Laboratories, PerkinElmer, Inc., Syngene International Limited, GenScript, Taconic Biosciences, Synthego Corporation, ATUM, Horizon Discovery, Genomatix AG +39 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular PhoenixBio employee's phone or email?
The PhoenixBio annual revenue was $9.8 million in 2026.
Takashi Shimada is the President and CEO of PhoenixBio.
9 people are employed at PhoenixBio.
PhoenixBio is based in Higashi Hiroshima, Hiroshima.
The NAICS codes for PhoenixBio are [32541, 3254, 325, 32].
The SIC codes for PhoenixBio are [283, 28].